CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest

Abstract Background Cell cycle dysregulation is common in human malignancies, and CDK4/6 inhibitors targeting cell cycle have potential antitumor activity. SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. However, the role of SHR6390 in esophageal squamous cell...

Full description

Bibliographic Details
Main Authors: Jiayuan Wang, Qingqing Li, Jiajia Yuan, Jingyuan Wang, Zuhua Chen, Zhentao Liu, Zhongwu Li, Yumei Lai, Jing Gao, Lin Shen
Format: Article
Language:English
Published: BMC 2017-06-01
Series:Journal of Translational Medicine
Subjects:
CDK4/6 inhibitor
ESCC
Cell cycle arrest
pRb
Online Access:http://link.springer.com/article/10.1186/s12967-017-1231-7

Internet

http://link.springer.com/article/10.1186/s12967-017-1231-7

Similar Items